287 related articles for article (PubMed ID: 27678053)
41. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
[TBL] [Abstract][Full Text] [Related]
42. Multivariate Analysis of Genotype-Phenotype Association.
Mitteroecker P; Cheverud JM; Pavlicev M
Genetics; 2016 Apr; 202(4):1345-63. PubMed ID: 26896328
[TBL] [Abstract][Full Text] [Related]
43. Novel drug resistance mutations in HIV: recognition and clinical relevance.
Perno CF; Svicher V; Ceccherini-Silberstein F
AIDS Rev; 2006; 8(4):179-90. PubMed ID: 17219733
[TBL] [Abstract][Full Text] [Related]
44. Physical Constraints on Epistasis.
Husain K; Murugan A
Mol Biol Evol; 2020 Oct; 37(10):2865-2874. PubMed ID: 32421772
[TBL] [Abstract][Full Text] [Related]
45. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
[TBL] [Abstract][Full Text] [Related]
46. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.
Morand-Joubert L; Charpentier C; Poizat G; Chêne G; Dam E; Raguin G; Taburet AM; Girard PM; Hance AJ; Clavel F
Antivir Ther; 2006; 11(2):143-54. PubMed ID: 16640095
[TBL] [Abstract][Full Text] [Related]
47. QTL-based evidence for the role of epistasis in evolution.
Malmberg RL; Mauricio R
Genet Res; 2005 Oct; 86(2):89-95. PubMed ID: 16356282
[TBL] [Abstract][Full Text] [Related]
48. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
[TBL] [Abstract][Full Text] [Related]
49. Is modularity necessary for evolvability? Remarks on the relationship between pleiotropy and evolvability.
Hansen TF
Biosystems; 2003 May; 69(2-3):83-94. PubMed ID: 12689723
[TBL] [Abstract][Full Text] [Related]
50. The contribution of epistatic pleiotropy to the genetic architecture of covariation among polygenic traits in mice.
Wolf JB; Pomp D; Eisen EJ; Cheverud JM; Leamy LJ
Evol Dev; 2006; 8(5):468-76. PubMed ID: 16925682
[TBL] [Abstract][Full Text] [Related]
51. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus.
Gandhi RT; Wurcel A; Rosenberg ES; Johnston MN; Hellmann N; Bates M; Hirsch MS; Walker BD
Clin Infect Dis; 2003 Dec; 37(12):1693-8. PubMed ID: 14689353
[TBL] [Abstract][Full Text] [Related]
52. Pervasive, yet idiosyncratic, epistatic pleiotropy during adaptation in a behaviourally complex microbe.
Zee PC; Liu J; Velicer GJ
J Evol Biol; 2017 Feb; 30(2):257-269. PubMed ID: 27862537
[TBL] [Abstract][Full Text] [Related]
53. Genetic determinants and epistasis for life history trait differences in the common monkeyflower, Mimulus guttatus.
Friedman J
J Hered; 2014; 105(6):816-27. PubMed ID: 25189775
[TBL] [Abstract][Full Text] [Related]
54. Evo-Devo-EpiR: a genome-wide search platform for epistatic control on the evolution of development.
Jiang L; Zhang M; Sang M; Ye M; Wu R
Brief Bioinform; 2017 Sep; 18(5):754-760. PubMed ID: 27473062
[TBL] [Abstract][Full Text] [Related]
55. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence.
Martínez-Cajas JL; Pant-Pai N; Klein MB; Wainberg MA
AIDS Rev; 2008; 10(4):212-23. PubMed ID: 19092977
[TBL] [Abstract][Full Text] [Related]
56. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
57. Epistasis and pleiotropy-induced variation for plant breeding.
Dwivedi SL; Heslop-Harrison P; Amas J; Ortiz R; Edwards D
Plant Biotechnol J; 2024 Jun; ():. PubMed ID: 38875130
[TBL] [Abstract][Full Text] [Related]
58. Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.
Kagan RM; Sista P; Pattery T; Bacheler L; Schwab DA
AIDS; 2009 Jul; 23(12):1602-5. PubMed ID: 19474648
[TBL] [Abstract][Full Text] [Related]
59. Moderate prevalence of transmitted drug resistance and high HIV-1 genetic diversity in patients from Mato Grosso State, Central Western Brazil.
Ferreira AS; Cardoso LP; Stefani MM
J Med Virol; 2011 Aug; 83(8):1301-7. PubMed ID: 21678433
[TBL] [Abstract][Full Text] [Related]
60. Using C-JAMP to Investigate Epistasis and Pleiotropy.
Konigorski S; Glicksberg BS
Methods Mol Biol; 2021; 2212():225-243. PubMed ID: 33733359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
